[EN] COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY<br/>[FR] COMPOSÉS POUR TRAITER LA DYSTROPHIE MUSCULAIRE DE DUCHENNE
申请人:SUMMIT CORP PLC
公开号:WO2009013477A1
公开(公告)日:2009-01-29
Compounds of general formula (I), wherein X1, X2, X3, R1, R2, R3, Y and Z are as defined herein are useful for the treatment and prevention of Duchenne muscular dystrophy, Becker muscular dystrophy and cachexia.
COMPOUNDS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY
申请人:Summit Corporation Plc
公开号:EP2167508A1
公开(公告)日:2010-03-31
INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE AND METHODS FOR THEIR USE
申请人:Koong Albert C.
公开号:US20090312362A1
公开(公告)日:2009-12-17
Compounds that are inhibitors of the unfolded protein response and endonuclease IRE1 are provided, together with compositions comprising such compounds, and methods for their use in the treatment of various disorders, such as cancer, autoimmune disorders, and diabetes. Also provided are packaged pharmaceuticals comprising these compositions. The compositions may be administered in combination with another therapeutic agent.
US8372861B2
申请人:——
公开号:US8372861B2
公开(公告)日:2013-02-12
[EN] INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE LA REPONSE AUX PROTEINES NON DEPLIEES ET PROCEDES D'UTILISATION
申请人:UNIV LELAND STANFORD JUNIOR
公开号:WO2007101224A2
公开(公告)日:2007-09-07
[EN] Compounds that are inhibitors of the unfolded protein response and endonuclease IRE1 are provided, together with compositions comprising such compounds, and methods for their use in the treatment of various disorders, such as cancer, autoimmune disorders, and diabetes. Also provided are packaged pharmaceuticals comprising these compositions. The compositions may be administered in combination with another therapeutic agent. [FR] L'invention porte sur des inhibiteurs de la réponse aux protéines dépliées et sur l'endonucléase IRE1, ainsi que sur des compositions renfermant lesdits composés, et sur des procédés associés utilisés pour traiter diverses pathologies, telles que le cancer, les maladies autoimmunes et le diabète. L'invention porte également sur des produits pharmaceutiques conditionnés renfermant lesdites compositions. Ces compositions peuvent être administrées en combinaison avec un autre agent thérapeutique.